NPS Pharmaceuticals, Inc.
) reported fourth quarter 2012 net loss per share of 14 cents,
wider than the Zacks Consensus Estimate of a loss of 9 cents and
the year-ago loss of 10 cents. The wider loss was primarily
attributable to higher expenses.
Fourth quarter 2012 revenues climbed 3.5% to $27.2 million.
Revenues constitute of royalties as well as milestones and
license fees. Revenues were below the Zacks Consensus Estimate of
In the fourth quarter of 2012 research and development
expenses were $24 million, up 11.1%. The increase was
attributable to higher personnel-related expenses incurred during
the final quarter of 2012. In 2012 general and administrative
expenses were $11.2 million, up 55.5%.
Full year 2012 net loss per share was 22 cents compared with
45 cents of loss per share in 2011. The Zacks Consensus Estimate
for 2012 hinted at a net loss of 16 cents per share. Revenues in
2012 increased 28.5% year over year to $130.6 million. Revenues
for 2012 missed the Zacks Consensus Estimate of $134 million.
We note that the company received encouraging news during the
final quarter of 2012 when the US Food and Drug Administration
(FDA) approved Gattex® (teduglutide). The drug was cleared for
the treatment of adults with short bowel syndrome (SBS), who are
dependent on a parenteral support.
NPS Pharma is also developing Natpara (rhPTH[1-84]) for the
treatment of adult hypoparathyroidism and expects to submit its
Biologic License Application (BLA) to the FDA in the second half
Total operating expenses, including share-based compensation
are expected in the range $135 million to $145 million in
NPS carries a Zacks Rank #3 (Hold). Currently, companies like
Lannett Company, Inc.
SIGA Technologies, Inc.
United Therapeutics Corporation
) look more attractive with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
NPS PHARMA INC (NPSP): Free Stock Analysis
SIGA TECH INC (SIGA): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.